181 related articles for article (PubMed ID: 37233208)
1. Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging.
Samykutty A; Thomas KN; McNally M; Hagood J; Chiba A; Thomas A; McWilliams L; Behkam B; Zhan Y; Council-Troche M; Claros-Sorto JC; Henson C; Garwe T; Sarwar Z; Grizzle WE; McNally LR
Radiol Imaging Cancer; 2023 May; 5(3):e220180. PubMed ID: 37233208
[TBL] [Abstract][Full Text] [Related]
2.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
3. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
4. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores.
Sano K; Mitsunaga M; Nakajima T; Choyke PL; Kobayashi H
Breast Cancer Res; 2012; 14(2):R61. PubMed ID: 22510481
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin-targeted probe detects orthotopic breast cancers using optoacoustic imaging.
Samykutty A; Thomas A; McNally M; Chiba A; McNally LR
Biotech Histochem; 2018; 93(8):608-614. PubMed ID: 30260254
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract][Full Text] [Related]
7. Development of Gold Nanorods Conjugated with Radiolabeled Anti-human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody as Single-Photon Emission Computed Tomography/Photoacoustic Dual-Imaging Probes Targeting HER2-Positive Tumors.
Ding N; Sano K; Shimizu Y; Watanabe H; Namita T; Shiina T; Ono M; Saji H
Biol Pharm Bull; 2020; 43(12):1859-1866. PubMed ID: 33268703
[TBL] [Abstract][Full Text] [Related]
8. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
9. Optical imaging of cancer heterogeneity with multispectral optoacoustic tomography.
Herzog E; Taruttis A; Beziere N; Lutich AA; Razansky D; Ntziachristos V
Radiology; 2012 May; 263(2):461-8. PubMed ID: 22517960
[TBL] [Abstract][Full Text] [Related]
10. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
11. Multispectral optoacoustic tomography of the human breast: characterisation of healthy tissue and malignant lesions using a hybrid ultrasound-optoacoustic approach.
Becker A; Masthoff M; Claussen J; Ford SJ; Roll W; Burg M; Barth PJ; Heindel W; Schäfers M; Eisenblätter M; Wildgruber M
Eur Radiol; 2018 Feb; 28(2):602-609. PubMed ID: 28786007
[TBL] [Abstract][Full Text] [Related]
12. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
13. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation.
Neuschmelting V; Harmsen S; Beziere N; Lockau H; Hsu HT; Huang R; Razansky D; Ntziachristos V; Kircher MF
Small; 2018 Jun; 14(23):e1800740. PubMed ID: 29726109
[TBL] [Abstract][Full Text] [Related]
14. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
15. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography.
Copland JA; Eghtedari M; Popov VL; Kotov N; Mamedova N; Motamedi M; Oraevsky AA
Mol Imaging Biol; 2004; 6(5):341-9. PubMed ID: 15380744
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
Lambertini M; Campbell C; Bines J; Korde LA; Izquierdo M; Fumagalli D; Del Mastro L; Ignatiadis M; Pritchard K; Wolff AC; Jackisch C; Lang I; Untch M; Smith I; Boyle F; Xu B; Barrios CH; Baselga J; Moreno-Aspitia A; Piccart M; Gelber RD; de Azambuja E
J Natl Cancer Inst; 2019 Jan; 111(1):86-94. PubMed ID: 29878225
[TBL] [Abstract][Full Text] [Related]
17. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
Gee MS; Upadhyay R; Bergquist H; Alencar H; Reynolds F; Maricevich M; Weissleder R; Josephson L; Mahmood U
Radiology; 2008 Sep; 248(3):925-35. PubMed ID: 18647846
[TBL] [Abstract][Full Text] [Related]
18. Dual-Labeled Near-Infrared/(99m)Tc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells.
Yamaguchi H; Tsuchimochi M; Hayama K; Kawase T; Tsubokawa N
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399687
[TBL] [Abstract][Full Text] [Related]
19. Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes.
Dogan BE; Menezes GLG; Butler RS; Neuschler EI; Aitchison R; Lavin PT; Tucker FL; Grobmyer SR; Otto PM; Stavros AT
Radiology; 2019 Sep; 292(3):564-572. PubMed ID: 31287388
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
